Any current/future new fundraising through debt or equity?

The transcript does not mention any specific plans for new fundraising through debt or equity in the near term. Current net debt stands at Rs. 2,633 crores, with a target to reduce the net debt to EBITDA ratio to less than 2.5 by March 2025. CAPEX of around Rs. 1800 to Rs. 2000 crores is planned over the next two years, primarily funded by advances from customers for specific CMO capacity expansions and internal resources. The company is prioritizing investments into high-value business segments and improving working capital efficiency without indicating the need for immediate external f

Any current/future capex/capital investment/strategic investment?

Capex planned for FY24 and FY25 is around Rs. 1800 to Rs. 2000 crores, mainly directed toward CDMO and finished dosage formulations (FDF) expansion. Additional FDF capacity expansion at Unit-2 in Vizag: increasing from 10 billion to 13 billion tablets over 18 months, driven by specific customer CMO contracts, mostly for generic products; majority of this CAPEX will be funded by customer advances. Rs. 200 crore investment planned into fermentation facility at Vizag, expected to be commissioned by mid-2026, focusing on GMP pharmaceutical manufacturing. Ongoing investment in new R&D center at Gen

Future growth expectations in sales/revenue/volumes?

Q1 FY25 revenue was flattish at Rs. 1,195 crores, expected to pick up in H2 FY25 due to clinical phase project deliveries. Oncology APIs growing strongly, with Q1 sales up 120% YoY; new oncology products validated, awaiting regulatory approvals. ARV franchise expected to remain stable at around Rs. 2,400-2,500 crores annually. CDMO business anticipates healthy growth supported by late-stage NCE project deliveries scheduled in Q4 FY25. Commercial supplies from about 10 products ongoing; new registrations and late-stage projects indicate commercial volumes likely from FY26. Expansion plans (form

Future growth expectations in earnings/operating earnings/profits/EPS?

FY25 expected to be a good year with better performance in H2; Q1 aligns with internal guidance (Page 10). FY26 anticipated to be a much better year, driven by assets like Animal Health starting to yield results (Page 10). EBITDA margins expected to improve in H2 FY25 from current subdued levels due to lower asset utilization and investments (Page 6). Gross margins maintained around 50% for 8 quarters with confidence to sustain despite pricing pressures (Page 14). CDMO business expected to grow with scheduled deliveries of clinical phase projects primarily in Q4 FY25, contributing to revenues

Current/ Expected Orderbook/ Pending Orders?

The current order book for Laurus Labs' product basket looks encouraging, supported by additional supply contracts secured through successful tenders. The company is working on over 70 active CDMO projects. They have on-hand orders for clinical phase project deliveries expected mostly in H2 FY25. CDMO commercial deliveries base is about Rs. 200 crores per quarter, excluding new order opportunities. New CDMO commercial orders are expected to start contributing significantly from FY26 onwards. For ARVs, about $100 million sales occur with 25% formulation capacity utilization. Some ke

IN US

Sale is live|00:00:00left today

Laurus Labs LtdQ2 FY24Pharmaceuticals & Biotechnology

Laurus Labs Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,450P/E: 80.4Market Cap: ₹71.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Q1 FY25 revenue was flattish at Rs. 1,195 crores, expected to pick up in H2 FY25 due to clinical phase project deliveries.
→Oncology APIs growing strongly, with Q1 sales up 120% YoY; new oncology products validated, awaiting regulatory approvals.
→ARV franchise expected to remain stable at around Rs. 2,400-2,500 crores annually.
→CDMO business anticipates healthy growth supported by late-stage NCE project deliveries scheduled in Q4 FY25.
→Commercial supplies from about 10 products ongoing; new registrations and late-stage projects indicate commercial volumes likely from FY26.
→Expansion plans (formulations, fermentation facility at Vizag, animal health, crop protection) targeting medium to long-term growth.
→Pipeline includes 62 products under review/development with significant addressable market value.
→CMO collaborations and expanded oral solid dosage manufacturing lines expected to contribute to future revenue growth.

Margin guidance

Category 3

→FY25 expected to be a good year with better performance in H2; Q1 aligns with internal guidance (Page 10).
→FY26 anticipated to be a much better year, driven by assets like Animal Health starting to yield results (Page 10).
→EBITDA margins expected to improve in H2 FY25 from current subdued levels due to lower asset utilization and investments (Page 6).
→Gross margins maintained around 50% for 8 quarters with confidence to sustain despite pricing pressures (Page 14).
→CDMO business expected to grow with scheduled deliveries of clinical phase projects primarily in Q4 FY25, contributing to revenues beyond base Rs. 200 crores per quarter (Pages 10, 14).
→Continued investments of Rs. 1800-2000 crores planned over next 2 years, focusing on CDMO and FDF expansions (Page 14).
→Diluted EPS for Q1 FY25 at Rs. 0.23 with anticipated growth thereafter (Page 6).

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any specific plans for new fundraising through debt or equity in the near term.
→Current net debt stands at Rs. 2,633 crores, with a target to reduce the net debt to EBITDA ratio to less than 2.5 by March 2025.
→CAPEX of around Rs. 1800 to Rs. 2000 crores is planned over the next two years, primarily funded by advances from customers for specific CMO capacity expansions and internal resources.
→The company is prioritizing investments into high-value business segments and improving working capital efficiency without indicating the need for immediate external funding.
→No explicit mention of fresh equity issuance or debt raising during this period was found in the transcript.

Order book

→The current order book for Laurus Labs' product basket looks encouraging, supported by additional supply contracts secured through successful tenders.
→The company is working on over 70 active CDMO projects.
→They have on-hand orders for clinical phase project deliveries expected mostly in H2 FY25.
→CDMO commercial deliveries base is about Rs. 200 crores per quarter, excluding new order opportunities.
→New CDMO commercial orders are expected to start contributing significantly from FY26 onwards.
→For ARVs, about $100 million sales occur with 25% formulation capacity utilization.
→Some key late-phase NCE projects have scheduled deliveries expected in Q4 FY25.
→Expansion plans include additional CMO contracts which will add capacity and are backed by confirmed volumes and pricing, ensuring business stability.
→Joint venture with KRKA and new customer partnerships support order visibility and capacity utilization growth.

Capex plans

Yes

→Capex planned for FY24 and FY25 is around Rs. 1800 to Rs. 2000 crores, mainly directed toward CDMO and finished dosage formulations (FDF) expansion.
→Additional FDF capacity expansion at Unit-2 in Vizag: increasing from 10 billion to 13 billion tablets over 18 months, driven by specific customer CMO contracts, mostly for generic products; majority of this CAPEX will be funded by customer advances.
→Rs. 200 crore investment planned into fermentation facility at Vizag, expected to be commissioned by mid-2026, focusing on GMP pharmaceutical manufacturing.
→Ongoing investment in new R&D center at Genome Valley to support expanded CDMO capabilities.
→Total historic CAPEX of Rs. 2600 crore of which around 75% is for CDMO projects, currently underutilized due to phased project execution.
→Long-term investments include Animal Health and Crop Protection Ingredients facilities, with Crop Protection qualification targeted by end FY25.

How does Laurus Labs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Laurus Labs Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Laurus Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio